Hung-Mo Lin

1 month ago | jci.org | Svenja Weiss |Hung-Mo Lin |Eric Acosta |Natalia L. Komarova |Ping Chen |Dominik Wodarz | +10 more

AbstractEarly antibody therapy can prevent severe SARS-CoV-2 infection (COVID-19). However, the effectiveness of COVID-19 convalescent plasma (CCP) therapy in treating severe COVID-19 remains inconclusive. To test a hypothesis that some CCP units are associated with a coagulopathy hazard in severe disease that offsets its benefits, we tracked 304 CCP units administered to 414 hospitalized COVID-19 patients to assess their association with the onset of unfavorable post-transfusion D-dimer trends.